Table 1 Baseline characteristics
Rivaroxaban 10 mg bid/ 15 mg od N = 23 | Rivaroxaban 15 mg bid/ 15 mg od N = 55 | UFH/warfarin N = 19 | |
|---|---|---|---|
Sex, male, n (%) | 16 (69.6) | 25 (45.5) | 10 (52.6) |
Age, years, mean (SD) | 65.0 (9.9) | 68.8 (12.2) | 63.4 (18.3) |
Body weight <70 kg, n (%) | 15 (65.2) | 41 (74.5) | 15 (78.9) |
Creatinine clearance <80 ml/min, n (%) | 9 (39.1) | 36 (65.5) | 11 (57.9) |
DVT only, n (%) | 23 (100.0) | 25 (45.5) | 12 (63.2) |
Unprovoked VTE, n (%) | 11 (47.8) | 31 (56.4) | 8 (42.1) |
Provoked VTE, n (%) | 12 (52.2) | 24 (43.6) | 11 (57.9) |
Previous VTE, n (%) | 0 | 8 (14.5) | 1 (5.3) |
Recent surgery or trauma, n (%) | 6 (26.1) | 11 (20.0) | 2 (10.5) |
Active cancer, n (%) | 2 (8.7) | 3 (5.5) | 2 (10.5) |
Thrombophilia, n (%) | 2 (8.7) | 1 (1.8) | 3 (15.8) |
Protein S deficiency | 0 | 0 | 1 (5.3 %) |
Protein C deficiency | 1 (4.3) | 1 (1.8) | 2 (10.5) |
Antithrombin deficiency | 1 (4.3) | 0 | 0 |
Prolonged immobilization, n (%) | 3 (13.0) | 8 (14.5) | 4 (21.1) |
Intended treatment duration | |||
3 months, n (%) | 4 (17.4) | 10 (18.2) | 4 (21.1) |
6 months, n (%) | 12 (52.2) | 26 (47.3) | 9 (47.4) |
12 months, n (%) | 7 (30.4) | 19 (34.5) | 6 (31.6) |
Mean treatment duration, days (SD) | 191.8 (106.9) | 196.6 (121.7) | 199.8 (101.9) |
Adherence to study treatment | |||
Missing n (%) | 1 (4.3) | 0 | 0 |
≥50% to <80% | 0 | 0 | 4 (21.1) |
≥80% | 22 (95.7) | 55 (100.0) | 15 (78.9) |